Wei Ran, Wang Weihao, Huang Xiusheng, Qiao Jingtao, Huang Jinghe, Xing Chang, Pan Qi, Guo Lixin
Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China.
Peking University Fifth School of Clinical Medicine, Beijing, China.
Diabetol Metab Syndr. 2023 Aug 19;15(1):173. doi: 10.1186/s13098-023-01141-7.
To assess the cost-effectiveness of utilizing IDegLira in comparison to other treatment regimens ( liraglutide and degludec) in managing type 2 diabetes, taking into account the Chinese healthcare system's perspective.
The clinical data were obtained from the randomized controlled trials (RCTs) of the DUAL I and DUAL II evidence studies that took place in China. To estimate the lifetime quality-adjusted life-years (QALYs) and direct medical costs of patients receiving different treatment strategies from a long-term perspective, the IQVIA CORE Diabetes Model version 9.0 (IQVIA, Basel, Switzerland) was utilized. The costs were evaluated from the perspective of the China National Health System. Future costs and clinical benefits were discounted annually at 5%, and sensitivity analyses were conducted.
IDegLira was projected to reduce the incidence of diabetes-related complications and improve quality-adjusted life expectancy (QALE) versus liraglutide and degludec. A survival benefit was observed with IDegLira over Liraglutide (0.073 years). Lifetime costs were lower by Chinese yuan (CNY) 27,945 on IDegLira than on Liraglutide therapy. A similar survival benefit was observed with IDegLira over degludec (0.068 years). Lifetime costs were lower by CNY 1196 on IDegLira than on degludec therapy. Therefore, IDegLira was found to be cost-effective versus liraglutide and degludec with incremental cost-effectiveness ratios of Dominant per QALY gained, respectively, under the threshold of three times the gross domestic product (GDP) per capita in China.
IDegLira is a cost-effective hypoglycemic treatment option that delivers positive clinical outcomes while also reducing costs for Chinese patients living with type 2 diabetes.
从中国医疗体系的角度评估与其他治疗方案（利拉鲁肽和德谷胰岛素）相比，使用德谷胰岛素利拉鲁肽治疗2型糖尿病的成本效益。
临床数据来自在中国进行的DUAL I和DUAL II证据研究的随机对照试验（RCT）。为了从长期角度估计接受不同治疗策略患者的终生质量调整生命年（QALY）和直接医疗成本，使用了IQVIA核心糖尿病模型9.0版（IQVIA，瑞士巴塞尔）。成本从中国国家卫生系统的角度进行评估。未来成本和临床效益按每年5%进行贴现，并进行敏感性分析。
与利拉鲁肽和德谷胰岛素相比，预计德谷胰岛素利拉鲁肽可降低糖尿病相关并发症的发生率，并改善质量调整预期寿命（QALE）。与利拉鲁肽相比，德谷胰岛素利拉鲁肽有生存获益（0.073年）。德谷胰岛素利拉鲁肽治疗的终生成本比利拉鲁肽治疗低27,945元人民币。与德谷胰岛素相比，德谷胰岛素利拉鲁肽有类似的生存获益（0.068年）。德谷胰岛素利拉鲁肽治疗的终生成本比德谷胰岛素治疗低1196元人民币。因此，在中国人均国内生产总值（GDP）三倍的阈值下，德谷胰岛素利拉鲁肽与利拉鲁肽和德谷胰岛素相比具有成本效益，每获得一个QALY的增量成本效益比分别为显性。
德谷胰岛素利拉鲁肽是一种具有成本效益的降糖治疗选择，可为中国2型糖尿病患者带来积极的临床结果，同时降低成本。
